- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.12.25 | Genmab shelves Phase III lung cancer candidate | ||
| 30.12.25 | Johnson & Johnson acquires Halda Therapeutics for $3.05bn | ||
| 29.12.25 | Sanofi buys hep B vaccine maker for $2.2bn | ||
| 29.12.25 | Revamping best-selling drugs to combat patent cliff has limits | ||
| 29.12.25 | Innovent receives NMPA approval for Tabosun colon cancer treatment | ||
| 26.12.25 | Gilead Sciences to acquire Repare's RP-3467 | ||
| 24.12.25 | Zydus and Bioeq partner for commercialisation of Nufymco in US | ||
| 23.12.25 | Ipsen outlays $1bn for China-based Simcere's preclinical ADC | ||
| 23.12.25 | Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma | ||
| 23.12.25 | Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity | ||
| 23.12.25 | Samsung Biologics to acquire Human Genome Sciences | ||
| 22.12.25 | BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push | ||
| 22.12.25 | UK approves Gilead's twice-yearly HIV PrEP drug | ||
| 22.12.25 | Trump administration ties pricing deals with another nine pharma companies | ||
| 22.12.25 | Cytokinetics receives FDA approval for MYQORZO tablets for oHCM | ||
| 22.12.25 | AstraZeneca pulls Andexxa from US market after post-marketing fatalities | ||
| 22.12.25 | MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan | ||
| 22.12.25 | Novartis, US government reach agreement to lower drug prices | ||
| 19.12.25 | Nxera seeks schizophrenia programme buyer after Boehringer snub | ||
| 19.12.25 | Takeda to seek approval of plaque psoriasis pill on Phase III trial data | ||
| 19.12.25 | Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs | ||
| 19.12.25 | MHRA launches call for evidence on AI regulation in UK healthcare sector | ||
| 19.12.25 | J&J receives FDA approval for lung cancer therapy | ||
| 18.12.25 | FDA approves meningioma label warning on Pfizer's contraceptive injection | ||
| 18.12.25 | BIOSECURE Act set for Trump's signature after Congress approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .